{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:12:38Z","timestamp":1778271158742,"version":"3.51.4"},"reference-count":28,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with multiple myeloma have an elevated risk of severe complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) infection. To demonstrate proof of concept for a pandemic preparedness and response network, the American Society of Hematology Research Collaborative Multiple Myeloma Program developed a prospective, decentralized study within a site-based provider network. In the COVID-19 outcomes in myeloma and the impact of vaccines (COSMIC) study, patients provided consent, permitted electronic health record data collection, completed patient-reported outcomes at baseline, day 30, and day 180 through an electronic study portal, and were compensated for participation. Clinicians at participating sites facilitated study recruitment and shared best practices monthly to accelerate study execution. The COSMIC study rapidly consented 201 patients from 8 participating sites over 4 months (22 January 2024 through 17 May 2024). Consented participants were 30 to 93 years old, with a median age of 67; 46% were female, 69% were non-Hispanic White, 17% were non-Hispanic Black, and 8% were Hispanic\/Latino. Patient-reported data completion was 97% at baseline, 81% at 1 month, and 79% at 6 months. At baseline, 55% of patients reported a history of COVID-19 infection and had received a median of 4 SARS-CoV-2 vaccines. For all patients, there were an additional 18 COVID-19 infections and 57 vaccines received during the 6-month observation period. There were no significant differences in health-related quality of life over time or by history of COVID-19 infection. COSMIC demonstrates the feasibility of an innovative evidence generation strategy to drive rapid accrual of patients to address an evolving area of need. This trial was registered at www.clinicaltrials.gov as #NCT05831787.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018963","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T22:07:59Z","timestamp":1771970879000},"page":"3094-3102","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7439-2543","authenticated-orcid":false,"given":"William A.","family":"Wood","sequence":"first","affiliation":[{"name":"1Division of Hematology, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"2Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily A.","family":"Semmel","sequence":"additional","affiliation":[{"name":"3ASH Research Collaborative, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shandra","family":"James","sequence":"additional","affiliation":[{"name":"3ASH Research Collaborative, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"4Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-839X","authenticated-orcid":false,"given":"David J.","family":"Chung","sequence":"additional","affiliation":[{"name":"5Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0714-734X","authenticated-orcid":false,"given":"Aaron","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, University of California, Davis, Sacramento, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Zonder","sequence":"additional","affiliation":[{"name":"7Karmanos Cancer Institute, Detroit, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-5643","authenticated-orcid":false,"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"8Division of Hematology\/Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"9Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"9Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[{"name":"4Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[{"name":"10Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"11Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[{"name":"11Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[{"name":"12Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Torres","sequence":"additional","affiliation":[{"name":"3ASH Research Collaborative, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan M.","family":"Weiss","sequence":"additional","affiliation":[{"name":"13Moderna, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-8882","authenticated-orcid":false,"given":"Levi","family":"Pederson","sequence":"additional","affiliation":[{"name":"2Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[{"name":"5Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Geyer","sequence":"additional","affiliation":[{"name":"2Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"5Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"23","key":"2026050815171900300_bib1","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1182\/bloodadvances.2021005902","article-title":"ASH research collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology","volume":"5","author":"Wood","year":"2021","journal-title":"Blood Adv"},{"issue":"15","key":"2026050815171900300_bib2","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/bloodadvances.2023010035","article-title":"A pandemic preparedness network for individuals living with compromised immune systems","volume":"7","author":"Wood","year":"2023","journal-title":"Blood Adv"},{"key":"2026050815171900300_bib3","volume-title":"Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action","year":"2020"},{"issue":"9","key":"2026050815171900300_bib4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"2026050815171900300_bib5","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","article-title":"Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016","volume":"178","author":"Moore","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"22","key":"2026050815171900300_bib6","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-10-1273","article-title":"Phase III clinical trial development: a process of chutes and ladders","volume":"16","author":"Dilts","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026050815171900300_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/bloodadvances.2024015532","article-title":"Accelerating novel therapies for sickle cell disease with RWE: ASH RC Data Hub as a strategically coordinated registry network","volume":"10","author":"Wood","year":"2026","journal-title":"Blood Adv"},{"issue":"26","key":"2026050815171900300_bib7","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.2020008150","article-title":"Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set","volume":"136","author":"Chari","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2026050815171900300_bib8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2643-3230.BCD-20-0102","article-title":"COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers","volume":"1","author":"Hultcrantz","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"13","key":"2026050815171900300_bib9","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/bloodadvances.2021004288","article-title":"Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease","volume":"5","author":"Mucalo","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2026050815171900300_bib10","doi-asserted-by":"crossref","first-page":"e240288","DOI":"10.1001\/jamanetworkopen.2024.0288","article-title":"Severe COVID-19 in vaccinated adults with hematologic cancers in the Veterans Health Administration","volume":"7","author":"Anand","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2026050815171900300_bib11","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/blood.2021013768","article-title":"Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting","volume":"139","author":"Mittelman","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2026050815171900300_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"2026050815171900300_bib27","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"The Lancet Oncol"},{"issue":"5","key":"2026050815171900300_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2026050815171900300_bib14","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"issue":"23","key":"2026050815171900300_bib15","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1182\/bloodadvances.2020003170","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub","volume":"4","author":"Wood","year":"2020","journal-title":"Blood Adv"},{"key":"2026050815171900300_bib26","unstructured":"Digital Health Technologies for Remote Data Acquisition in Clinical Investigations. U.S. Food and Drug Administration. Accessed 3 March 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/digital-health-technologies-remote-data-acquisition-clinical-investigations."},{"issue":"3","key":"2026050815171900300_bib16","doi-asserted-by":"crossref","first-page":"e007767","DOI":"10.1161\/CIRCHEARTFAILURE.120.007767","article-title":"Novel trial design: CHIEF-HF","volume":"14","author":"Spertus","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"4","key":"2026050815171900300_bib17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"2026050815171900300_bib18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/amiajnl-2014-002747","article-title":"Launching PCORnet, a national patient-centered clinical research network","volume":"21","author":"Fleurence","year":"2014","journal-title":"J Am Med Inform Assoc"},{"issue":"7","key":"2026050815171900300_bib19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMsr1809937","article-title":"The \u201cAll of Us\u201d research program","volume":"381","author":"Denny","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"2026050815171900300_bib20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaoncol.2021.0540","article-title":"Disparities in electronic health record patient portal enrollment among oncology patients","volume":"7","author":"Sinha","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"2026050815171900300_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"2026050815171900300_bib22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026050815171900300_bib23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"2026050815171900300_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx029","article-title":"Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients","volume":"109","author":"Denis","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"2026050815171900300_bib25","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1001\/archinte.165.19.2272","article-title":"Effect of a clinical trial alert system on physician participation in trial recruitment","volume":"165","author":"Embi","year":"2005","journal-title":"Arch Intern Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3094\/2516184\/blooda_adv-2025-018963r1-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3094\/2516184\/blooda_adv-2025-018963r1-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:17:28Z","timestamp":1778267848000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3094\/566832\/Feasibility-of-decentralized-real-world-monitoring"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018963","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,5,1]]}}}